<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01013285</url>
  </required_header>
  <id_info>
    <org_study_id>11-000558</org_study_id>
    <secondary_id>UCLA-0604016</secondary_id>
    <secondary_id>AVF3770s</secondary_id>
    <secondary_id>CDR0000628787</secondary_id>
    <secondary_id>GENENTECH-UCLA-0604016</secondary_id>
    <nct_id>NCT01013285</nct_id>
  </id_info>
  <brief_title>Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma</brief_title>
  <official_title>Phase II Trial of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the&#xD;
      growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such&#xD;
      as temozolomide, work in different ways to stop the growth of tumor cells, either by killing&#xD;
      the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to&#xD;
      kill tumor cells. Giving bevacizumab together with temozolomide and radiation therapy may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects and how well giving bevacizumab&#xD;
      together with temozolomide and external beam radiation therapy works when given as first-line&#xD;
      therapy in treating patients with newly diagnosed glioblastoma multiforme or gliosarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To investigate the safety and tolerability of bevacizumab in combination with&#xD;
           temozolomide and external beam fractionated regional radiotherapy as first-line&#xD;
           treatment in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.&#xD;
           (Pilot phase)&#xD;
&#xD;
        -  To estimate the overall survival of patients treated with this regimen. (Expansion&#xD;
           phase)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To further investigate the safety and tolerability of this regimen in these patients.&#xD;
           (Expansion phase)&#xD;
&#xD;
        -  To isolate DNA, RNA, and protein from frozen and paraffin-embedded archival tumor&#xD;
           samples for evaluations, such as immunohistochemical pathway profiling of vascular&#xD;
           endothelial growth factor (VEGF)-dependent angiogenic pathways, gene expression&#xD;
           microarray, and O-6 methylguanine DNA methyltransferase (MGMT) promoter methylation&#xD;
           status to define important molecular features of treatment response.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients undergo external beam fractionated regional radiotherapy once daily 5 days a week&#xD;
      for 6 weeks and receive concurrent oral temozolomide once daily for 6 weeks. Patients also&#xD;
      receive bevacizumab IV over 30-90 minutes every 2 weeks beginning on the first day of&#xD;
      radiotherapy and continuing in the absence of disease progression or unacceptable toxicity.&#xD;
      Beginning 2-5 weeks after completion of radiotherapy, patients receive oral temozolomide on&#xD;
      days 1-5. Treatment with temozolomide repeats every 28 days for up to 24 courses in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood and frozen and paraffin-embedded tumor tissue samples are collected for biomarker and&#xD;
      genetic analysis.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>2 years</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>participants who were alive and disease progression free at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Response (When Evaluable)</measure>
    <time_frame>2 years</time_frame>
    <description>Radiation therapy (RT) median from diagnosis to RT. Patients will have brain MRI evaluation of response and progression every 8 weeks starting from the day 56 scan obtained 2 weeks after completion of radiation and daily temozolomide and assessment will be conducted on a 7-point scale. This scale is expected to be more useful in this study because many newly-diagnosed patients are likely not to have evaluable disease due to gross total resections. Determination of whether progression occurs based on the day 56 scan will take into account the untreated window between baseline MRI and day of 1 of study.&#xD;
7 Point Likert Scale: 3 to -3, 3 means complete resolution of tumor, and -3 means new lesion. A -2 or -3 assessment will be taken as tumor progression.&#xD;
complete resolution of tumor: 3&#xD;
tumor resolved 3 tumor definitely smaller: 2 tumor probably smaller: 1 tumor unchanged: 0 tumor probably worse: -1 tumor definitely worse: -2 New Lesion: -3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival (OS) Based on the MGMT Promoter Methylation Status</measure>
    <time_frame>2 years</time_frame>
    <description>IDH1 and MGMT methylation are important independent prognostic biomarkers that have to be included in a Cox regression model. In addition, subgroup analysis could reveal differential sensitivities to the treatment arm. The MGMT promoter methylation status, IDH1 mutation status were not available for all of the control samples. Therefore, only the samples with both info available were included in the analysis. Baseline analysis results are included in the Baseline Characteristics module.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>bevacizumab, temozolomide, external beam radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <arm_group_label>bevacizumab, temozolomide, external beam radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <arm_group_label>bevacizumab, temozolomide, external beam radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>external beam radiation therapy</intervention_name>
    <arm_group_label>bevacizumab, temozolomide, external beam radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed intracranial glioblastoma multiforme (GBM) or gliosarcoma.&#xD;
&#xD;
          -  Prior histologic diagnosis of low-grade glioma allowed provided it has been upgraded&#xD;
             to GBM after repeat resection&#xD;
&#xD;
          -  Has undergone surgery to collect tumor tissue 3-6 weeks ago&#xD;
&#xD;
          -  Measurable or assessable disease is not required&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Life expectancy &gt; 8 weeks&#xD;
&#xD;
          -  White Blood Cell (WBC) ≥ 3,000/mm³&#xD;
&#xD;
          -  Absolute Neutrophil Count (ANC) ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL (transfusion allowed)&#xD;
&#xD;
          -  Serum Glutamate Oxaloacetate Transaminase (SGOT) &lt; 2.5 times upper limit of normal&#xD;
             (ULN)&#xD;
&#xD;
          -  Bilirubin &lt; 2.5 times ULN&#xD;
&#xD;
          -  INR (international normalized ratio) ≤ 1.5 times ULN (except if on therapeutic&#xD;
             anticoagulation therapy)&#xD;
&#xD;
          -  aPTT (activated partial thromboplastin time) ≤ 1.5 times ULN (except if on therapeutic&#xD;
             anticoagulation therapy)&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Urine protein:creatinine ratio &lt; 1.0&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  More than 28 days since prior major surgical procedures or open biopsy (other than&#xD;
             craniotomy)&#xD;
&#xD;
          -  More than 7 days since prior minor surgical procedures (e.g., placement of PortoCath&#xD;
             (port-a-cath - a port placed under the subjects skin), stereotactic biopsy,&#xD;
             fine-needle aspirations, or core biopsies)&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent participation in another experimental&#xD;
             drug study.&#xD;
&#xD;
          -  Prior or concurrent corticosteroids, anti-epileptic drugs, analgesics, or other drugs&#xD;
             to treat symptoms or prevent complications are allowed&#xD;
&#xD;
          -  Concurrent full-dose warfarin or its equivalent (i.e., unfractionated and/or low&#xD;
             molecular weight heparin) allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unstable angina&#xD;
&#xD;
          -  BP &gt; 150/100 mm Hg&#xD;
&#xD;
          -  New York Heart Association (NYHA) class II-IV congestive heart failure&#xD;
&#xD;
          -  myocardial infarction within the past 6 months&#xD;
&#xD;
          -  stroke within the past 6 months&#xD;
&#xD;
          -  clinically significant peripheral vascular disease&#xD;
&#xD;
          -  evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  intracerebral abscess within past 6 months&#xD;
&#xD;
          -  abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the&#xD;
             past 6 months&#xD;
&#xD;
          -  serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Any wound requiring surgical intervention (including scalp wounds requiring&#xD;
             cranioplasty) allowed provided the wound is clean and without further infection&#xD;
             post-surgical intervention&#xD;
&#xD;
          -  significant traumatic injury within the past 28 days&#xD;
&#xD;
          -  concurrent serious uncontrolled medical illness including, but not limited to, the&#xD;
             following:&#xD;
&#xD;
          -  Ongoing or active infection requiring IV antibiotics&#xD;
&#xD;
          -  Psychiatric illness/social situation that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  Disorders associated with significant immunocompromised state (e.g., HIV, systemic&#xD;
             lupus erythematosus)&#xD;
&#xD;
          -  other cancer within the past 3 years, except nonmelanoma skin cancer or carcinoma in&#xD;
             situ of the cervix&#xD;
&#xD;
          -  disease that would obscure toxicity or dangerously alter drug metabolism&#xD;
&#xD;
          -  significant medical illness that, in the investigator's opinion, cannot be adequately&#xD;
             controlled with appropriate therapy or would compromise the patient's ability to&#xD;
             tolerate study therapy&#xD;
&#xD;
          -  prior radiotherapy to the brain&#xD;
&#xD;
          -  prior cytotoxic or non-cytotoxic drug therapy or experimental drug therapy for the&#xD;
             brain tumor&#xD;
&#xD;
          -  prior Gliadel wafers&#xD;
&#xD;
          -  concurrent participation in any other clinical trial&#xD;
&#xD;
          -  concurrent GM-CSF (granulocyte-macrophage colony-stimulating factor)&#xD;
&#xD;
          -  concurrent stereotactic radiosurgery or brachytherapy&#xD;
&#xD;
          -  concurrent major surgical procedure&#xD;
&#xD;
          -  other concurrent anticancer therapy, including chemotherapy, hormonal therapy,&#xD;
             radiotherapy, or immunotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Lai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ronald Reagan University of California, Los Angeles (UCLA) Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, University of California, Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>November 11, 2009</study_first_submitted>
  <study_first_submitted_qc>November 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2009</study_first_posted>
  <results_first_submitted>February 25, 2016</results_first_submitted>
  <results_first_submitted_qc>August 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 21, 2020</results_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Seventy patients with newly diagnosed Glioblastoma Multiforme were enrolled between August 2006 and November 2008 from two participating sites, comprised of University of California, Los Angeles (UCLA) and Kaiser Permanente Los Angeles.</recruitment_details>
      <pre_assignment_details>Control cohort was derived from University of California, Los Angeles/Kaiser Permanente Los Angeles patients treated with first-line radiation therapy and temozolomide who had mostly received bevacizumab at recurrence.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm</title>
          <description>bevacizumab&#xD;
temozolomide&#xD;
external beam radiation therapy</description>
        </group>
        <group group_id="P2">
          <title>Historical Control UCLA/KPLA</title>
          <description>A University of California, Los Angeles/Kaiser Permanente Los Angeles(KPLA) control cohort of newly diagnosed patients treated with first-line radiation therapy and temozolomide who had mostly received bevacizumab at recurrence was derived for comparison.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm</title>
          <description>bevacizumab&#xD;
temozolomide&#xD;
external beam radiation therapy</description>
        </group>
        <group group_id="B2">
          <title>Historical Control UCLA/Kaiser</title>
          <description>A University of California, Los Angeles/Kaiser Permanente Los Angeles(KPLA) control cohort of newly diagnosed patients treated with first-line radiation therapy and temozolomide who had mostly received bevacizumab at recurrence was derived for comparison. Data excluded where records not complete</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="110"/>
            <count group_id="B3" value="180"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.4" lower_limit="31.3" upper_limit="75.8"/>
                    <measurement group_id="B2" value="59.4" lower_limit="20.5" upper_limit="90"/>
                    <measurement group_id="B3" value="59.305" lower_limit="20.5" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Enrollment by Site</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>UCLA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KPLA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky performance status</title>
          <description>Karnofsky performance status:&#xD;
100: Normal no complaints; no evidence of disease. 90: Able to carry on normal activity; minor signs or symptoms of disease. 80: Normal activity with effort; some signs or symptoms of disease. 70: Cares for self; unable to carry on normal activity or to do active work. 60: Requires occasional assistance, but is able to care for most of his personal needs. 100 best, the lower the number the worse outcome.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Extent of surgery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Biopsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subtotal resection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gross total resection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Recursive partitioning analysis by class</title>
          <description>According to a 2003 study, glioblastoma multiforme prognosis can be divided into three subgroups dependent on Karnofsky Performance Status (KPS), the age of the patient, and treatment.&#xD;
MST= Median Survival Time in months. III: Age &lt; 50, KPS ≥ 90; IV: Age &lt; 50, KPS &lt; 90, Age ≥ 50, KPS ≥ 70, surgical removal, good neurologic function;&#xD;
V + VI, Age ≥ 50, KPS ≥ 70, surgical removal with poor neurologic function:&#xD;
Age ≥ 50, KPS ≥ 70, no surgical removal. Age ≥ 50, KPS &lt; 70</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>III: MST 17.1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV: MST 11.2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V: MST 7.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VI: MST 7.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Follow-up</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.2" lower_limit="12" upper_limit="40"/>
                    <measurement group_id="B2" value="41.8" lower_limit="29" upper_limit="58"/>
                    <measurement group_id="B3" value="36.616" lower_limit="12" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Deaths</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Recurrent treatment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Progressed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressed with chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressed with bevacizumab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MGMT (O-6-Methylguanine-DNA Methyltransferase) promoter methylation</title>
          <description>The MGMT (O-6-Methylguanine-DNA Methyltransferase) promoter methylation status was not available for all of the historical control samples. Therefore, only the samples with the information available were included.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Methylated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unmethylated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IDH1 (Isocitrate dehydrogenase 1 ) mutational status</title>
          <description>[1] The IDH1 (Isocitrate dehydrogenase 1 ) promoter methylation status was not available for all of the historical control samples. Therefore, only the samples with the information available were included.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Wild type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IDH1-R132H mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>bevacizumab&#xD;
temozolomide&#xD;
external beam radiation therapy</description>
          </group>
          <group group_id="O2">
            <title>Historical Control UCLA/KPLA</title>
            <description>A University of California, Los Angeles/Kaiser Permanente Los Angeles(KPLA) control cohort of newly diagnosed patients treated with first-line radiation therapy and temozolomide who had mostly received bevacizumab at recurrence was derived for comparison.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" lower_limit="16.1" upper_limit="23.3"/>
                    <measurement group_id="O2" value="21.1" lower_limit="18.9" upper_limit="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>bevacizumab&#xD;
temozolomide&#xD;
external beam radiation therapy</description>
          </group>
          <group group_id="O2">
            <title>Historical Control UCLA/KPLA</title>
            <description>A University of California, Los Angeles/Kaiser Permanente Los Angeles(KPLA) control cohort of newly diagnosed patients treated with first-line radiation therapy and temozolomide who had mostly received bevacizumab at recurrence was derived for comparison.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="11.1" upper_limit="16.5"/>
                    <measurement group_id="O2" value="7.6" lower_limit="5.9" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival at 6 Months</title>
        <description>participants who were alive and disease progression free at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>bevacizumab&#xD;
temozolomide&#xD;
external beam radiation therapy</description>
          </group>
          <group group_id="O2">
            <title>Historical Control UCLA/KPLA</title>
            <description>A University of California, Los Angeles/Kaiser Permanente Los Angeles(KPLA) control cohort of newly diagnosed patients treated with first-line radiation therapy and temozolomide who had mostly received bevacizumab at recurrence was derived for comparison.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival at 6 Months</title>
          <description>participants who were alive and disease progression free at 6 months</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.4" lower_limit="81.17" upper_limit="96.3"/>
                    <measurement group_id="O2" value="58.3" lower_limit="49.7" upper_limit="68.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiographic Response (When Evaluable)</title>
        <description>Radiation therapy (RT) median from diagnosis to RT. Patients will have brain MRI evaluation of response and progression every 8 weeks starting from the day 56 scan obtained 2 weeks after completion of radiation and daily temozolomide and assessment will be conducted on a 7-point scale. This scale is expected to be more useful in this study because many newly-diagnosed patients are likely not to have evaluable disease due to gross total resections. Determination of whether progression occurs based on the day 56 scan will take into account the untreated window between baseline MRI and day of 1 of study.&#xD;
7 Point Likert Scale: 3 to -3, 3 means complete resolution of tumor, and -3 means new lesion. A -2 or -3 assessment will be taken as tumor progression.&#xD;
complete resolution of tumor: 3&#xD;
tumor resolved 3 tumor definitely smaller: 2 tumor probably smaller: 1 tumor unchanged: 0 tumor probably worse: -1 tumor definitely worse: -2 New Lesion: -3</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>bevacizumab&#xD;
temozolomide&#xD;
external beam radiation therapy</description>
          </group>
          <group group_id="O2">
            <title>Historical Control UCLA/KPLA</title>
            <description>A University of California, Los Angeles/Kaiser Permanente Los Angeles(KPLA) control cohort of newly diagnosed patients treated with first-line radiation therapy and temozolomide who had mostly received bevacizumab at recurrence was derived for comparison.</description>
          </group>
        </group_list>
        <measure>
          <title>Radiographic Response (When Evaluable)</title>
          <description>Radiation therapy (RT) median from diagnosis to RT. Patients will have brain MRI evaluation of response and progression every 8 weeks starting from the day 56 scan obtained 2 weeks after completion of radiation and daily temozolomide and assessment will be conducted on a 7-point scale. This scale is expected to be more useful in this study because many newly-diagnosed patients are likely not to have evaluable disease due to gross total resections. Determination of whether progression occurs based on the day 56 scan will take into account the untreated window between baseline MRI and day of 1 of study.&#xD;
7 Point Likert Scale: 3 to -3, 3 means complete resolution of tumor, and -3 means new lesion. A -2 or -3 assessment will be taken as tumor progression.&#xD;
complete resolution of tumor: 3&#xD;
tumor resolved 3 tumor definitely smaller: 2 tumor probably smaller: 1 tumor unchanged: 0 tumor probably worse: -1 tumor definitely worse: -2 New Lesion: -3</description>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" lower_limit="3" upper_limit="6.9"/>
                    <measurement group_id="O2" value="5" lower_limit="1.7" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival (OS) Based on the MGMT Promoter Methylation Status</title>
        <description>IDH1 and MGMT methylation are important independent prognostic biomarkers that have to be included in a Cox regression model. In addition, subgroup analysis could reveal differential sensitivities to the treatment arm. The MGMT promoter methylation status, IDH1 mutation status were not available for all of the control samples. Therefore, only the samples with both info available were included in the analysis. Baseline analysis results are included in the Baseline Characteristics module.</description>
        <time_frame>2 years</time_frame>
        <population>Description: Kaplan-Meier analysis of overall survival was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>bevacizumab&#xD;
temozolomide&#xD;
external beam radiation therapy</description>
          </group>
          <group group_id="O2">
            <title>Historical Control UCLA/KPLA</title>
            <description>A University of California, Los Angeles/Kaiser Permanente Los Angeles(KPLA) control cohort of newly diagnosed patients treated with first-line radiation therapy and temozolomide who had mostly received bevacizumab at recurrence was derived for comparison.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival (OS) Based on the MGMT Promoter Methylation Status</title>
          <description>IDH1 and MGMT methylation are important independent prognostic biomarkers that have to be included in a Cox regression model. In addition, subgroup analysis could reveal differential sensitivities to the treatment arm. The MGMT promoter methylation status, IDH1 mutation status were not available for all of the control samples. Therefore, only the samples with both info available were included in the analysis. Baseline analysis results are included in the Baseline Characteristics module.</description>
          <population>Description: Kaplan-Meier analysis of overall survival was performed.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median Overall survival of MGMT Methylated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" lower_limit="11.7" upper_limit="38.2"/>
                    <measurement group_id="O2" value="26.7" lower_limit="3.5" upper_limit="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Overall survival of MGMT Unmethylated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" lower_limit="5.7" upper_limit="31.5"/>
                    <measurement group_id="O2" value="18.2" lower_limit="2.1" upper_limit="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data collected through study completion, 2.25 years.</time_frame>
      <desc>period coinciding with Aug 23, 2006 - Nov 26, 2008</desc>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab, Temozolomide, External Beam Radiation</title>
          <description>bevacizumab&#xD;
temozolomide&#xD;
external beam radiation therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTCAE V.3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Nephritic proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>congestive heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Ventriculoperitoneal shunt placement.</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Falling episode/syncopal episode status post fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Left retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute inferior wall MI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Bowel perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Gastroenteritis due to E. coli.</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>GI Bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Perforated sigmoid diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Acute dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>hypotention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fungal infection (Left lung)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Upper Resp. tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Craniotomy wound w/cerebrospinal fluid leak</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Wound dehisicence of frontal wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Steroid-induced psychosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>obstructive uropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI CTCAE V.3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Albert Lai</name_or_title>
      <organization>UCLA Neuro-Oncology Program</organization>
      <phone>310-825-5321</phone>
      <email>albertlai@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

